Level B· Emerging clinical evidence with positive signalsClinical TrialPubMedOpen access

Adipose-Derived Stem Cells as a Tool in Cell-Based Therapies.

Bajek A., Gurtowska N., Olkowska J., Kazmierski L., Maj M., Drewa T.

Clinical Trial on Immune Modulation, published in Arch Immunol Ther Exp (Warsz) (2016) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Arch Immunol Ther Exp (Warsz) (2016)
Country
Poland
Reported sample size
—
Source database
PubMed
PMID
27178663
PMCID
PMC5085986
DOI
10.1007/s00005-016-0394-x
Citations
129

Abstract (original English)

Recent development in stem cell isolation methods and expansion under laboratory conditions create an opportunity to use those aforementioned cells in tissue engineering and regenerative medicine. Particular attention is drawn towards mesenchymal stem cells (MSCs) being multipotent progenitors exhibiting several unique characteristics, including high proliferation potential, self-renewal abilities and multilineage differentiation into cells of mesodermal and non-mesodermal origin. High abundance of MSCs found in adipose tissue makes it a very attractive source of adult stem cells for further use in regenerative medicine applications. Despite immunomodulating properties of adipose-derived stem cells (ASCs) and a secretion of a wide variety of paracrine factors that facilitate tissue regeneration, effectiveness of stem cell therapy was not supported by the results of clinical trials. Lack of a single, universal stem cell marker, patient-to-patient variability, heterogeneity of ASC population combined with multiple widely different protocols of cell isolation and expansion hinder the ability to precisely identify and analyze biological properties of stem cells. The above issues contribute to conflicting data reported in literature. We will review the comprehensive information concerning characteristic features of ASCs. We will also review the regenerative potential and clinical ap

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
AdipocytesAdipose TissueAnimalsCell DifferentiationCell ProliferationCellular SenescenceClinical Trials as TopicHumansMesenchymal Stem CellsMice

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research